Lonza, the Basel-based contract development and manufacturing organization (CDMO), will take part in the Jefferies Global Healthcare Conference in London on 17 and 18 November 2026, with CEO Wolfgang Wienand scheduled to host a presentation and a subsequent question-and-answer session on 18 November from 15:30 to 15:55 GMT, according to a company announcement distributed via NEWMEDIAWIRE.
The appearance matters because Lonza sits at the center of the outsourced manufacturing supply chain that pharmaceutical and biotechnology companies rely on to turn experimental compounds into approved therapies. As the world’s leading CDMO dedicated to serving the healthcare industry, Lonza works across three continents with a global team of approximately 17,000 colleagues, excluding its Capsules & Health Ingredients business, alongside pharma and biotech partners. Management commentary at major investor conferences can therefore shape expectations not only for Lonza’s own shares, which trade on the SIX Swiss Exchange with a secondary listing on the Singapore Exchange, but also for the wider ecosystem of drug developers that depend on outsourced capacity.
For readers and investors, the most concrete takeaway is access. The session will be webcast live, and a replay will remain available on the Lonza Investor Relations website for 90 days. The live audio webcast can be accessed via this link, giving shareholders, analysts and industry observers a direct channel to hear the CEO’s priorities and field questions. Such webcasts are often the first place where strategy updates and demand trends become public, and the archived replay extends the reach to investors who cannot tune in during the London trading day.
The timing of the conference also places Lonza’s remarks against a substantial financial backdrop. The company generated sales of CHF 3.4 billion with a CORE EBITDA of CHF 1.2 billion in Half-Year 2026, figures that underscore the scale of its manufacturing network and the importance of its customer relationships. Details about the company and its capabilities are available at www.lonza.com, and the original release can be viewed on www.newmediawire.com.
Why does a 25-minute conference slot matter? For an industry where manufacturing capacity, quality systems and reliable delivery determine whether therapies reach patients, signals from a leading CDMO’s chief executive carry weight across the healthcare value chain. Lonza’s participation in London is a scheduled, on-the-record opportunity for the market to hear how the company intends to build on its first-half performance and to gauge the health of demand for outsourced development and manufacturing services.
